Market Overview

Jazz Pharma Begins Trial of IV Administered Erwinaze

Related JAZZ
Next Year Setting Up To Be Smooth For Jazz Pharmaceuticals
Shkreli Thinks The Mylan-Epipen Controversy Is 'Not Very Fair'
Biotech Forum Daily Digest: Behind Some Big Moves In Small Caps. Spotlight On Vascular Biogenics (Seeking Alpha)

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the first patient has been enrolled and dosed in a clinical trial of Erwinaze^® (asparaginase Erwinia chrysanthemi) administered intravenously (IV) as an alternative method of administration to treat patients with acute lymphoblastic leukemia (ALL) with hypersensitivity to E. coli-derived asparaginase therapy.

Posted-In: News FDA


Related Articles (JAZZ)

View Comments and Join the Discussion!